On Sep. 25th, Upper Biotech applied for IPO was accepted by Shanghai Stock Exchange. At present, it has 7 listed enterprise on STAR Market, 2 registered upcoming companies and 5 waitings.

Shenzhen New Industries Biomedical Engineering Co., LTD., which was officially listed on the Gem of Shenzhen Stock Exchange on May 12, 2020,realized 97,0101,600 yuan of revenue, an increase of 31.06% over the same period last year.

From August to September 2020, the COVID-19 testing products of 5 companies around the world are included in the World Health Organization (WHO) Emergency Use Listing, of which 4 are Chinese in vitro diagnostics.

A joint research team have together developed a SENSR (SENsitive Splint-based one-pot isothermal RNA detection) technology that allows anyone to easily and quickly diagnose COVID-19 based on the RNA sequence of the virus.

Using dried blood spot samples (DBS) is an accurate alternative to venous blood in detecting SARS-CoV-2 antibody tests, a new study by immunology experts at the University of Birmingham has found.

Caltech researchers have developed a new type of multiplexed test with a low-cost sensor that may enable the at-home diagnosis of a COVID infection through rapid analysis of small volumes of saliva or blood in less than 10 minutes.

From July to September, eight Chinese in vitro diagnostic companies have successively obtained Emergency Use Authorization(EUA) issued by US Food and Drug Administration (FDA) .

NGS cancer companion diagnostics is an emerging industry in China, and its industry concentration has gradually increased over the past 6 years around development.

Recently, Gofar issued a report (draft) on the acquisition of KOALSON, proposing to purchase the 99.9779% of KOALSON's shares held by eight people with the transaction price of about 356 million yuan by issuing shares and paying cash.

In Sep. 16th, Zhejiang Gongdong Medical Technology Co., Ltd. successfully listed on SSE (Shanghai Stock Exchange).

Recently, Gilead Sciences announced that it has reached a definitive agreement with the American biotechnology company Immunomedics (Nasdaq: IMMU).

An Imperial team has repurposed robotic technology normally used for synthetic biology research to help with testing for COVID-19.

An antibody test for the virus that causes COVID-19, developed by researchers at The University of Texas at Austin, is more accurate and can handle a much larger number of donor samples at lower overall cost than standard antibody tests currently in use.

A method that lights up tags attached to selected proteins can help to purify the proteins from a mixed protein pool.

Researchers compared lipoproteins and metabolites in the blood of COVID-19 patients and healthy subjects, revealing signs of multi-organ damage in patients that could someday help diagnose and treat COVID-19.